These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 26216889)
21. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795 [TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and Protective Potential of Mucosal Vaccine Formulations Based on Conserved Epitopes of Influenza A Viruses Fused to an Innovative Ring Nanoplatform in Mice and Chickens. Calzas C; Mao M; Turpaud M; Viboud Q; Mettier J; Figueroa T; Bessière P; Mangin A; Sedano L; Hervé PL; Volmer R; Ducatez MF; Bourgault S; Archambault D; Le Goffic R; Chevalier C Front Immunol; 2021; 12():772550. PubMed ID: 34868036 [TBL] [Abstract][Full Text] [Related]
24. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration. de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989 [TBL] [Abstract][Full Text] [Related]
25. [Chitosan as an adjuvant for parenteral inactivated influenza vaccines]. Gendon IuZ; Markushin SG; Krivtsov GG; Akopova II Vopr Virusol; 2008; 53(5):14-9. PubMed ID: 19069787 [TBL] [Abstract][Full Text] [Related]
26. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA). Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805 [TBL] [Abstract][Full Text] [Related]
27. Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice. Zhang J; Fan HY; Zhang Z; Zhang J; Zhang J; Huang JN; Ye Y; Liao M Vaccine; 2016 Jan; 34(5):622-629. PubMed ID: 26724200 [TBL] [Abstract][Full Text] [Related]
32. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections. Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130 [TBL] [Abstract][Full Text] [Related]
33. Oral immunization of haemaggulutinin H5 expressed in plant endoplasmic reticulum with adjuvant saponin protects mice against highly pathogenic avian influenza A virus infection. Lee G; Na YJ; Yang BG; Choi JP; Seo YB; Hong CP; Yun CH; Kim DH; Sohn EJ; Kim JH; Sung YC; Kim YK; Jang MH; Hwang I Plant Biotechnol J; 2015 Jan; 13(1):62-72. PubMed ID: 25065685 [TBL] [Abstract][Full Text] [Related]
34. Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection. Patel A; Gray M; Li Y; Kobasa D; Yao X; Kobinger GP Vaccine; 2012 Jan; 30(3):626-36. PubMed ID: 22119588 [TBL] [Abstract][Full Text] [Related]
35. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Price GE; Soboleski MR; Lo CY; Misplon JA; Pappas C; Houser KV; Tumpey TM; Epstein SL Vaccine; 2009 Nov; 27(47):6512-21. PubMed ID: 19729082 [TBL] [Abstract][Full Text] [Related]
36. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. Staneková Z; Király J; Stropkovská A; Mikušková T; Mucha V; Kostolanský F; Varečková E Acta Virol; 2011; 55(1):61-7. PubMed ID: 21434706 [TBL] [Abstract][Full Text] [Related]
37. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689 [TBL] [Abstract][Full Text] [Related]
38. Protective cellular and mucosal immune responses following nasal administration of a whole gamma-irradiated influenza A (subtype H1N1) vaccine adjuvanted with interleukin-28B in a mouse model. Sabbaghi A; Zargar M; Zolfaghari MR; Motamedi-Sedeh F; Ghaemi A Arch Virol; 2021 Feb; 166(2):545-557. PubMed ID: 33409549 [TBL] [Abstract][Full Text] [Related]
39. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. Shim BS; Choi YK; Yun CH; Lee EG; Jeon YS; Park SM; Cheon IS; Joo DH; Cho CH; Song MS; Seo SU; Byun YH; Park HJ; Poo H; Seong BL; Kim JO; Nguyen HH; Stadler K; Kim DW; Hong KJ; Czerkinsky C; Song MK PLoS One; 2011; 6(11):e27953. PubMed ID: 22140491 [TBL] [Abstract][Full Text] [Related]
40. Heterosubtypic protection against influenza A induced by adenylate cyclase toxoids delivering conserved HA2 subunit of hemagglutinin. Staneková Z; Adkins I; Kosová M; Janulíková J; Sebo P; Varečková E Antiviral Res; 2013 Jan; 97(1):24-35. PubMed ID: 23036818 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]